ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Migrasomes in Ischemic Stroke: Molecular Landscape and Pathophysiological Impact.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Migrasomes in Ischemic Stroke: Molecular Landscape and Pathophysiological Impact.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Ischemic stroke (IS) initiates complex systemic responses that extend beyond focal brain injury. To capture these multifaceted changes, proteomics, untargeted metabolomics, and lipidomics are integrated from IS patients spanning a range of clinical severities. This multi-omics approach reveals distinct molecular subtypes characterized by immune activation, oxidative stress, and metabolic dysregulation. Notably, elevated levels of migrasomes are identified in patient plasma and mouse brain tissue. Proteomic profiling of these migrasomes shows enrichment in complement, coagulation, and cholesterol-associated pathways. Functional assays further demonstrate that migrasomes derived from peripheral immune cells exacerbate ischemic injury and intensify post-stroke inflammation. Together, these findings position migrasomes as critical drivers of IS pathophysiology and highlight them as promising targets for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.